Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial

Journal:

The Lancet

Published:

2026-02-07

DOI:

10.1016/s0140-6736(25)01945-2

Affiliations:

15

Authors:

19

Go to article

Institutions	Authors	Share
Merck & Co, United States of America (USA)	9.000000	0.47
Queen Mary University of London (QMUL), United Kingdom (UK)	1.000000	0.05
Wentworth Hospital, South Africa	1.000000	0.05
Fundación Clínica Valle del Lili, Colombia	1.000000	0.05
Georgetown University Medical Center (GUMC), United States of America (USA)	1.000000	0.05
University of New South Wales (UNSW Sydney), Australia	1.000000	0.05
University Health Network (UHN), U of T, Canada	1.000000	0.05
University of Pennsylvania (Penn), United States of America (USA)	1.000000	0.05
Nagoya Medical Center, Japan	1.000000	0.05
St Vincent's Hospital Sydney, Australia	0.500000	0.03
Holdsworth House Medical Practice, Australia	0.500000	0.03
University Hospital Zurich (UHZ), Switzerland	0.333333	0.02
Klinik Hirslanden, Switzerland	0.333333	0.02
University of Zurich (UZH), Switzerland	0.333333	0.02

Interested in Clinical Sciences?